3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Nonclinical testing has served as a foundation for evaluating potential risks and
effectiveness of investigational new drugs in humans. However, the current two‐dimensional …
effectiveness of investigational new drugs in humans. However, the current two‐dimensional …
The role of “physiologically based pharmacokinetic model (PBPK)” new approach methodology (NAM) in pharmaceuticals and environmental chemical risk …
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally
employed in the pharmaceutical industry and environmental health risk assessment. These …
employed in the pharmaceutical industry and environmental health risk assessment. These …
Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS)
MV Varma, SJ Steyn, C Allerton, AF El-Kattan - Pharmaceutical research, 2015 - Springer
Early prediction of clearance mechanisms allows for the rapid progression of drug discovery
and development programs, and facilitates risk assessment of the pharmacokinetic …
and development programs, and facilitates risk assessment of the pharmacokinetic …
[HTML][HTML] Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions
Metformin is used as a probe for OCT2 mediated transport when investigating possible DDIs
with new chemical entities. The aim of the current study was to investigate the ability of …
with new chemical entities. The aim of the current study was to investigate the ability of …
Evaluation of pharmacokinetic drug–drug interactions: a review of the mechanisms, in vitro and in silico approaches
Y Peng, Z Cheng, F Xie - Metabolites, 2021 - mdpi.com
Pharmacokinetic drug–drug interactions (DDIs) occur when a drug alters the absorption,
transport, distribution, metabolism or excretion of a co-administered agent. The occurrence …
transport, distribution, metabolism or excretion of a co-administered agent. The occurrence …
Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1
J Vaidyanathan, K Yoshida, V Arya… - The Journal of Clinical …, 2016 - Wiley Online Library
Abstract Evaluation of organic anion transporting polypeptide (OATP) 1B1–mediated drug‐
drug interactions (DDIs) is an integral part of drug development and is recommended by …
drug interactions (DDIs) is an integral part of drug development and is recommended by …
Biomarker‐informed model‐based risk assessment of organic anion transporting polypeptide 1B mediated drug‐drug interactions
E Kimoto, C Costales, MA West, Y Bi… - Clinical …, 2022 - Wiley Online Library
Quantitative prediction of drug‐drug interactions (DDIs) involving organic anion transporting
polypeptide (OATP) 1B1/1B3 inhibition is limited by uncertainty in the translatability of …
polypeptide (OATP) 1B1/1B3 inhibition is limited by uncertainty in the translatability of …
Quantitative analyses of hepatic OATP‐mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method
This study aimed to construct a widely applicable method for quantitative analyses of drug–
drug interactions (DDIs) caused by the inhibition of hepatic organic anion transporting …
drug interactions (DDIs) caused by the inhibition of hepatic organic anion transporting …
Quantitative contribution of six major transporters to the hepatic uptake of drugs:“SLC-phenotyping” using primary human hepatocytes
Y Bi, C Costales, S Mathialagan, M West… - … of Pharmacology and …, 2019 - ASPET
Hepatic uptake transporters [solute carriers (SLCs)], including organic anion transporting
polypeptide (OATP) 1B1, OATP1B3, OATP2B1, sodium-dependent taurocholate …
polypeptide (OATP) 1B1, OATP1B3, OATP2B1, sodium-dependent taurocholate …
Reimagining the framework supporting the static analysis of transporter drug interaction risk; integrated use of biomarkers to generate pan‐transporter inhibition …
AD Rodrigues - Clinical Pharmacology & Therapeutics, 2023 - Wiley Online Library
Solute carrier (SLC) transporters present as the loci of important drug–drug interactions
(DDIs). Therefore, sponsors generate in vitro half‐maximal inhibitory concentration (IC50) …
(DDIs). Therefore, sponsors generate in vitro half‐maximal inhibitory concentration (IC50) …